Ignite Creation Date:
2025-12-24 @ 12:47 PM
Ignite Modification Date:
2025-12-27 @ 9:25 PM
Study NCT ID:
NCT05547061
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-12-11
First Post:
2022-09-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Sponsor:
Cellbion Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-12
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-09-13
First Submit QC Date:
None
Study First Post Date:
2022-09-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-09
Last Update Post Date:
2024-12-11
Last Update Post Date Type:
ACTUAL